By abhat@reaganud… on
Email
CompassionateAccess@gilead.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=Gilead&cntry=&state=&city=&dist=&Search=Search&recrs=c&recrs=k
Acknowledgement
30 days
EA Page
https://www.gilead.com/science-and-medicine/research/compassionate-use
Sponsor
Gilead
Gilead Sciences
U.S. Army Medical Research and Development Command
EA Policies for Disease / Category

Emergency Access to Remdesivir Outside of Clinical Trials

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection

Expanded Access Remdesivir (RDV; GS-5734™) - for DOD/military personnel only

Remdesivir Clinical Trials

COVID-19 Information

COVID-19 Resource Page

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection

Expanded Access Remdesivir (RDV; GS-5734™) - for DOD/military personnel only

Emergency Access to Remdesivir Outside of Clinical Trials

Remdesivir Clinical Trials

An Open Letter from our Chairman and CEO (March 28, 2020)

An Update on COVID-19 from our Chairman & CEO (April 4, 2020)

"Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations." 

 

Stage
Phase 2
Phase 3
Expanded Access
Company Type
Late Onset Intervention
Early Onset Intervention
Expanded Access Listings

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Conditions
Cystic Fibrosis
Pseudomonas Aeruginosa Airway Infection

The primary objective of this program is to provide expanded access to aztreonam lysinefor inhalation (AZLI) 75 mg prior to its commercial availability to patients with cysticfibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatmentoptions and are at risk for disease progression.

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Conditions
Chronic Lymphocytic Leukemia (CLL)

This study is to provide idelalisib (IDELA) to individuals with relapsed, previouslytreated chronic lymphocytic leukemia (CLL) who have limited treatment options and are noteligible for other Gilead-sponsored studies.

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

Conditions
SARS-CoV2 Infection

The primary objective of this study is to provide expanded access of remdesivir (RDV) forthe treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.